A Guangming enterprise has unveiled the world's first organoid 3D bioprinter, Bao'an Daily reported.

In April 2024, Organoid Med (Shenzhen) Biotech Co., Ltd. was founded by Dr. Chen Jianwei, a returned overseas scholar, and his core team at the Overseas Returnee Entrepreneurship Park in Guangming District. The company is at the forefront of merging organoid 3D bioprinting with artificial intelligence (AI) technologies, the report said.

Organoid Med's breakthrough platform encompasses core biomaterials, cutting-edge bioprinting equipment, and mainstream manufacturing processes. The company aims to lead the industry by integrating research and development, production, scientific services, and medical testing. 

“Many late-stage cancer patients lose valuable time on treatments that do not properly mimic human biology, and repairing organ damage remains a daunting clinical challenge,” explained Dr. Chen. “By combining organoid 3D bioprinting with AI, we are developing true human-response models that can accelerate clinical translation.”

The company has now focused on two core technologies. The first is organoid 3D printing, which uses stem or tumor cells to print miniature, functional organs—such as a beating heart model—at scale. The second is AI-driven digital twins for organoids and drug testing, simulating drug efficacy and toxicity by integrating multimodal organoid data with clinical information.

Dr. Chen highlighted Guangming Science City's robust hard-tech entrepreneurial ecosystem, competitive talent incentives, and strong industry support as key factors influencing his decision to base the company here.